Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

New Senate healthcare bill allows insurance plans with fewer benefits, keeps Medicaid cuts

Senate Republicans have released a new version of their Affordable Care Act (ACA) replacement plan, adding new funding for stabilizing the individual market and keeping more of the ACA’s taxes, while also including a controversial proposal to allow insurance plans which don’t comply with ACA regulations on benefits and community rating.

Thumbnail

House passes FDA user fee reauthorization, Senate schedule unclear

The House has passed legislation to reauthorize user fee programs through the Food and Drug Administration (FDA) affecting medical devices, prescription and generic drugs.

'Most Wired Survey' shows progress in tech utilization

Hospitals & Health Networks has released its 19th annual annual "Most Wired Survey," showcasing the nation’s top technological hospitals and health systems. The survey ranks facilities based on utilization of healthcare technologies including mobile health, telehealth, security system and innovation.

Thumbnail

AHIP: Market instability, higher premiums for sicker enrollees under Cruz amendment

America’s Health Insurance Plans (AHIP), health insurers’ largest lobbying group, has been largely silent on Senate Republicans’ version on an Affordable Care Act (ACA) replacement plan, but now is warning against a conservative amendment to allow insurers to now offer plans which don’t comply with ACA regulations.

Are value-based pharma contracts smoke and mirrors?

Pharmaceutical companies appear to be embracing contracts where they return money if patient outcomes don’t meet goals, but similar approaches haven’t lowered costs.

HHS approves Alaska reinsurance program to shore up ACA market

Alaska will receive $323 million from HHS from 2018 to 2022 for a reinsurance program to offset claims from high-cost patients for the lone insurer offering coverage on its Affordable Care Act exchange.

Thumbnail

Q&A with Experian exec: Embrace payment plans before going to collections

Jason Considine, senior vice president of patient collections and engagement at Experian Health, argued at the Healthcare Financial Management Association (HFMA) conference in Orlando that providers should first rely on leveraging data and crafting flexible payment options before paying any contingency fees to collectors. He spoke with HealthExec about mistakes providers are making with their collection practices and what data they need to improve the process.

Home visits reduce readmission in elderly patients

Having a home health worker can reduce rates of readmission for older patients, according to a study conducted by the Indiana University Center for Aging Research and Regenstrief Institute. Findings were presented in the Journal of the American Medical Directors Association.

Displaying 4449 - 4456 of 6649

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup